Energy Expenditure, Body Composition, and Obesity

Thursday, May 12, 2022

1:50 PM – 2:10 PM

Location: Breakout Room 2- Sapphire OP (Level 4)

Speaker(s)

Eric Ravussin, PhD
Associate Executive Director
Pennington Biomedical
Baton Rouge, United States

Disclosure: Amway (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Grant/Research Support (Status: Ongoing); Big Sky Health, Inc (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Generian Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Kintai Therapeutics (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Lilly (Self) : Grant/Research Support (Status: Ongoing); Merck Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Novartis (Self) : Grant/Research Support (Status: Ongoing); sanofi (Self) : Grant/Research Support (Status: Ongoing); YSOPIA (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

PDF Slides

Participants should be aware of the following financial/non-financial relationships:

Eric Ravussin, PhD: Amway (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Grant/Research Support; Big Sky Health, Inc (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Generian Pharmaceuticals (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Kintai Therapeutics (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Lilly (Individual(s) Involved: Self): Grant/Research Support; Merck Pharmaceuticals (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Novartis (Individual(s) Involved: Self): Grant/Research Support; sanofi (Individual(s) Involved: Self): Grant/Research Support; YSOPIA (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)